David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

"Aethlon Medical treats first subject with Hemopurifier device in Australia" was originally created and published by Medical ...

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ...

Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious ...

( MENAFN - Investor Ideas) Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech and medical tech Stocks reports on trading and news for Aethlon Medical, Inc ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...